Network-based identification of key master regulators associated with an immune-silent cancer phenotype

<div><p>A cancer immune phenotype characterized by an active T-helper 1 (Th1)/cytotoxic response is associated with responsiveness to immunotherapy and favorable prognosis across different tumors. However, in some cancers, such an intratumoral immune activation does not confer protection...

Full description

Saved in:
Bibliographic Details
Main Author: Raghvendra Mall (581171) (author)
Other Authors: Mohamad Saad (214545) (author), Jessica Roelands (7516439) (author), Darawan Rinchai (742366) (author), Khalid Kunji (828224) (author), Hossam Almeer (9771875) (author), Wouter Hendrickx (44559) (author), Francesco M Marincola (808) (author), Michele Ceccarelli (184154) (author), Davide Bedognetti (2632474) (author)
Published: 2021
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513515318935552
author Raghvendra Mall (581171)
author2 Mohamad Saad (214545)
Jessica Roelands (7516439)
Darawan Rinchai (742366)
Khalid Kunji (828224)
Hossam Almeer (9771875)
Wouter Hendrickx (44559)
Francesco M Marincola (808)
Michele Ceccarelli (184154)
Davide Bedognetti (2632474)
author2_role author
author
author
author
author
author
author
author
author
author_facet Raghvendra Mall (581171)
Mohamad Saad (214545)
Jessica Roelands (7516439)
Darawan Rinchai (742366)
Khalid Kunji (828224)
Hossam Almeer (9771875)
Wouter Hendrickx (44559)
Francesco M Marincola (808)
Michele Ceccarelli (184154)
Davide Bedognetti (2632474)
author_role author
dc.creator.none.fl_str_mv Raghvendra Mall (581171)
Mohamad Saad (214545)
Jessica Roelands (7516439)
Darawan Rinchai (742366)
Khalid Kunji (828224)
Hossam Almeer (9771875)
Wouter Hendrickx (44559)
Francesco M Marincola (808)
Michele Ceccarelli (184154)
Davide Bedognetti (2632474)
dc.date.none.fl_str_mv 2021-05-13T03:00:00Z
dc.identifier.none.fl_str_mv 10.1093/bib/bbab168
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Network-based_identification_of_key_master_regulators_associated_with_an_immune-silent_cancer_phenotype/25878028
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biological sciences
Genetics
Biomedical and clinical sciences
Oncology and carcinogenesis
transcription regulator
master regulator analysis
immunologic constant of rejection
immune exclusion
gene regulatory networks
dc.title.none.fl_str_mv Network-based identification of key master regulators associated with an immune-silent cancer phenotype
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <div><p>A cancer immune phenotype characterized by an active T-helper 1 (Th1)/cytotoxic response is associated with responsiveness to immunotherapy and favorable prognosis across different tumors. However, in some cancers, such an intratumoral immune activation does not confer protection from progression or relapse. Defining mechanisms associated with immune evasion is imperative to refine stratification algorithms, to guide treatment decisions and to identify candidates for immune-targeted therapy. Molecular alterations governing mechanisms for immune exclusion are still largely unknown. The availability of large genomic datasets offers an opportunity to ascertain key determinants of differential intratumoral immune response. We follow a network-based protocol to identify transcription regulators (TRs) associated with poor immunologic antitumor activity. We use a consensus of four different pipelines consisting of two state-of-the-art gene regulatory network inference techniques, regularized gradient boosting machines and ARACNE to determine TR regulons, and three separate enrichment techniques, including fast gene set enrichment analysis, gene set variation analysis and virtual inference of protein activity by enriched regulon analysis to identify the most important TRs affecting immunologic antitumor activity. These TRs, referred to as master regulators (MRs), are unique to immune-silent and immune-active tumors, respectively. We validated the MRs coherently associated with the immune-silent phenotype across cancers in The Cancer Genome Atlas and a series of additional datasets in the Prediction of Clinical Outcomes from Genomic Profiles repository. A downstream analysis of MRs specific to the immune-silent phenotype resulted in the identification of several enriched candidate pathways, including NOTCH1, TGF-$\beta $, Interleukin-1 and TNF-$\alpha $ signaling pathways. TGFB1I1 emerged as one of the main negative immune modulators preventing the favorable effects of a Th1/cytotoxic response.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Briefings in Bioinformatics<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1093/bib/bbab168" target="_blank">https://dx.doi.org/10.1093/bib/bbab168</a></p>
eu_rights_str_mv openAccess
id Manara2_d2d0958bd8d92a87f4c95fdd79938dbe
identifier_str_mv 10.1093/bib/bbab168
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/25878028
publishDate 2021
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Network-based identification of key master regulators associated with an immune-silent cancer phenotypeRaghvendra Mall (581171)Mohamad Saad (214545)Jessica Roelands (7516439)Darawan Rinchai (742366)Khalid Kunji (828224)Hossam Almeer (9771875)Wouter Hendrickx (44559)Francesco M Marincola (808)Michele Ceccarelli (184154)Davide Bedognetti (2632474)Biological sciencesGeneticsBiomedical and clinical sciencesOncology and carcinogenesistranscription regulatormaster regulator analysisimmunologic constant of rejectionimmune exclusiongene regulatory networks<div><p>A cancer immune phenotype characterized by an active T-helper 1 (Th1)/cytotoxic response is associated with responsiveness to immunotherapy and favorable prognosis across different tumors. However, in some cancers, such an intratumoral immune activation does not confer protection from progression or relapse. Defining mechanisms associated with immune evasion is imperative to refine stratification algorithms, to guide treatment decisions and to identify candidates for immune-targeted therapy. Molecular alterations governing mechanisms for immune exclusion are still largely unknown. The availability of large genomic datasets offers an opportunity to ascertain key determinants of differential intratumoral immune response. We follow a network-based protocol to identify transcription regulators (TRs) associated with poor immunologic antitumor activity. We use a consensus of four different pipelines consisting of two state-of-the-art gene regulatory network inference techniques, regularized gradient boosting machines and ARACNE to determine TR regulons, and three separate enrichment techniques, including fast gene set enrichment analysis, gene set variation analysis and virtual inference of protein activity by enriched regulon analysis to identify the most important TRs affecting immunologic antitumor activity. These TRs, referred to as master regulators (MRs), are unique to immune-silent and immune-active tumors, respectively. We validated the MRs coherently associated with the immune-silent phenotype across cancers in The Cancer Genome Atlas and a series of additional datasets in the Prediction of Clinical Outcomes from Genomic Profiles repository. A downstream analysis of MRs specific to the immune-silent phenotype resulted in the identification of several enriched candidate pathways, including NOTCH1, TGF-$\beta $, Interleukin-1 and TNF-$\alpha $ signaling pathways. TGFB1I1 emerged as one of the main negative immune modulators preventing the favorable effects of a Th1/cytotoxic response.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Briefings in Bioinformatics<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1093/bib/bbab168" target="_blank">https://dx.doi.org/10.1093/bib/bbab168</a></p>2021-05-13T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1093/bib/bbab168https://figshare.com/articles/journal_contribution/Network-based_identification_of_key_master_regulators_associated_with_an_immune-silent_cancer_phenotype/25878028CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/258780282021-05-13T03:00:00Z
spellingShingle Network-based identification of key master regulators associated with an immune-silent cancer phenotype
Raghvendra Mall (581171)
Biological sciences
Genetics
Biomedical and clinical sciences
Oncology and carcinogenesis
transcription regulator
master regulator analysis
immunologic constant of rejection
immune exclusion
gene regulatory networks
status_str publishedVersion
title Network-based identification of key master regulators associated with an immune-silent cancer phenotype
title_full Network-based identification of key master regulators associated with an immune-silent cancer phenotype
title_fullStr Network-based identification of key master regulators associated with an immune-silent cancer phenotype
title_full_unstemmed Network-based identification of key master regulators associated with an immune-silent cancer phenotype
title_short Network-based identification of key master regulators associated with an immune-silent cancer phenotype
title_sort Network-based identification of key master regulators associated with an immune-silent cancer phenotype
topic Biological sciences
Genetics
Biomedical and clinical sciences
Oncology and carcinogenesis
transcription regulator
master regulator analysis
immunologic constant of rejection
immune exclusion
gene regulatory networks